SciSparc Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SPRC Nasdaq 2830 scisparc.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SciSparc Ltd.

NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome - Oct 22nd, 2026 7:02 am
SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome - Oct 22nd, 2026 6:55 am
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications - Oct 19th, 2026 6:35 am
SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies - Oct 15th, 2026 5:06 am
SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture - Oct 7th, 2026 6:22 am
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations - Sep 23rd, 2026 6:35 am
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - Sep 2nd, 2026 7:16 am
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - Sep 2nd, 2026 6:17 am
NeuroThera Labs Achieves Significant Enrollment Momentum in SCI210 Autism Clinical Trial - Aug 31st, 2026 2:05 pm
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial - Aug 31st, 2026 2:03 pm
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Aug 31st, 2026 8:12 am
SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board - Aug 26th, 2026 6:32 am
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - Aug 24th, 2026 6:51 am
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million - Aug 18th, 2026 6:06 am
NeuroThera Labs Inc. Closes First Tranche of Non-Brokered Private Placement - Aug 12th, 2026 3:01 pm
NeuroThera Labs Granted Japanese Patent for Its Proprietary, Innovative Therapeutic Combination - Aug 12th, 2026 7:00 am
SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination - Aug 12th, 2026 6:25 am
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome - Aug 5th, 2026 6:22 am
SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics - Jul 31st, 2026 6:20 am